Pheochromocytoma and paraganglioma: imaging characteristics
Juan Carlos Báez(Brigham and Women's Hospital), Nikhil H. Ramaiya(Brigham and Women's Hospital), Katherine Zukotynski(Unknown), Katherine M. Krajewski(Brigham and Women's Hospital), Kevin O′Regan(Brigham and Women's Hospital), Jyothi P. Jagannathan(Brigham and Women's Hospital), Matthew H. Kulke(Moffitt Cancer Center)
Cited by 66
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
|Journal of Clinical Oncology|2018|388
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
|Nature Genetics|2013|374